SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Increase in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a significant growth in short interest in March. As of March 31st, there was short interest totalling 52,600 shares, a growth of 22.3% from the March 15th total of 43,000 shares. Based on an average daily volume of 54,500 shares, the short-interest ratio is currently 1.0 days. Currently, 0.1% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Several brokerages have commented on SOPH. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research note on Wednesday, March 6th. BTIG Research upped their price target on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, March 6th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in SOPHiA GENETICS during the second quarter worth $31,000. Renaissance Technologies LLC acquired a new position in SOPHiA GENETICS during the second quarter worth $63,000. JPMorgan Chase & Co. boosted its holdings in SOPHiA GENETICS by 3,090.2% during the fourth quarter. JPMorgan Chase & Co. now owns 31,392 shares of the company’s stock worth $65,000 after purchasing an additional 30,408 shares during the last quarter. Jane Street Group LLC acquired a new position in SOPHiA GENETICS during the first quarter worth $80,000. Finally, Two Sigma Securities LLC acquired a new position in SOPHiA GENETICS during the first quarter worth $90,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock opened at $5.00 on Monday. SOPHiA GENETICS has a twelve month low of $2.13 and a twelve month high of $7.37. The company has a 50 day moving average of $4.84 and a 200-day moving average of $4.31.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, March 5th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.12). SOPHiA GENETICS had a negative net margin of 126.63% and a negative return on equity of 47.40%. The company had revenue of $17.05 million during the quarter, compared to analyst estimates of $16.78 million. During the same quarter last year, the company earned ($0.22) EPS. As a group, analysts anticipate that SOPHiA GENETICS will post -1.06 EPS for the current fiscal year.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.